Access Bio (CEO Choi Young-ho), a global in vitro diagnostic company, announced on the 13th that Wellysis' patch-type electrocardiograph S-Patch Ex, with which it formed a strategic partnership last year, has received approval from the U.S. Food and Drug Administration (FDA). Access Bio previously made an investment by acquiring redeemable convertible preferred stock issued by Wellysis through Mason Healthcare New Technology Investment Association No. 2. The market expects that the solid global distribution network of Access Bio, headquartered in the United States, will play a significant role in Wellysis' entry into the United States through this approval.

In the future, Access Bio plans to expand its